Ori-CAR-002 is under clinical development by Origincell Technology Group and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ori-CAR-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene therapy is under development for the treatment of relapsed and refractory multiple myeloma. The therapeutic candidate comprises of T-cells genetically engineered to express chimeric antigen receptor (CAR) transduced with mini-F DNA origin (ori2) plasmid.
Origincell Technology Group overview
Origincell Technology Group is a manufactures biotechnology products. The company is headquartered in China.
For a complete picture of Ori-CAR-002’s drug-specific PTSR and LoA scores, buy the report here.